Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-Current Deffered Revenue: 2016-2024

Historic Non-Current Deffered Revenue for Akebia Therapeutics (AKBA) over the last 8 years, with Mar 2024 value amounting to $43.3 million.

  • Akebia Therapeutics' Non-Current Deffered Revenue changed negligibly% to $43.3 million in Q1 2024 from the same period last year, while for Mar 2024 it was $43.3 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $43.3 million for FY2023, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Akebia Therapeutics reported Non-Current Deffered Revenue of $43.3 million as of Q1 2024, which was down 0.00% from $43.3 million recorded in Q4 2023.
  • Akebia Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $65.4 million during Q1 2022, with a 5-year trough of $16.6 million in Q2 2021.
  • In the last 3 years, Akebia Therapeutics' Non-Current Deffered Revenue had a median value of $43.3 million in 2024 and averaged $45.7 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first tumbled by 54.91% in 2021, then spiked by 238.65% in 2022.
  • Quarterly analysis of 5 years shows Akebia Therapeutics' Non-Current Deffered Revenue stood at $25.3 million in 2020, then fell by 15.27% to $21.5 million in 2021, then skyrocketed by 101.62% to $43.3 million in 2022, then remained steady at $43.3 million in 2023, then remained steady at $43.3 million in 2024.
  • Its Non-Current Deffered Revenue was $43.3 million in Q1 2024, compared to $43.3 million in Q4 2023 and $43.3 million in Q3 2023.